Performance enhancing drug abuse and cardiovascular risk in athletes: Implications for the clinician

British Journal of Sports Medicine

Volumn 46, Issue SUPPL. 1, 2012, Pages

  Angell, Peter J ^a   Chester, Neil ^a   Sculthorpe, Nick ^b   Whyte, Greg ^a   George, Keith ^a   Somauroo, John ^a,c  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^c Countess of Chester Health Park ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; ANABOLIC AGENT; CENTRAL STIMULANT AGENT; PERFORMANCE ENHANCING SUBSTANCE;

ADDICTION; ADULT; ANGIOCARDIOGRAPHY; ATHLETE; CARDIOVASCULAR DISEASE; CASE REPORT; CHEMICALLY INDUCED DISORDER; COCAINE DEPENDENCE; DOPING; ELECTROCARDIOGRAPHY; HUMAN; REVIEW; RISK FACTOR;

ADULT; AMPHETAMINES; ANABOLIC AGENTS; ATHLETES; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE-RELATED DISORDERS; CORONARY ANGIOGRAPHY; DOPING IN SPORTS; ELECTROCARDIOGRAPHY; HUMANS; PERFORMANCE-ENHANCING SUBSTANCES; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84869059500     PISSN: 03063674     EISSN: 14730480     Source Type: Journal    
DOI: 10.1136/bjsports-2012-091186     Document Type: Article

References (81)

1. Yesalis CE, Bahrke M. History of doping in sport. Performance enhancing substances in sport and exercise. Champaign: Human Kinetics, 2002:1-20.
2. WADA. The 2012 prohibited list International Standard. http://wwwwada-amaorg/Documents/World-Anti-Doping-Program/WADP-Prohibited-list/ 2012/WADA-Prohibited-List-2012-ENpdf (serial on the Internet), 2012.
3. Calfee R, Fadale P. Popular ergogenic drugs and supplements in young athletes. Pediatrics 2006;117:e577.
4. WADA-2010-Laboratory-Statistics-Report.pdf.
5. Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: a regional study. Eur J Intern Med 2006;17:479-84. (Pubitemid 44708733)
6. Sader MA, Griffiths KA, McCredie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol 2001;37:224-30. (Pubitemid 32051743)
7. McVeigh J, Beynon C, Bellis MA. New challenges for agency based syringe exchange schemes: analysis of 11 years of data (1991-2001) in Merseyside and Cheshire, United Kingdom. Int J Drug Policy 2003;14:399-405. (Pubitemid 37412236)
8. Angell P, Chester N, Green D, et al. Anabolic steroids and cardiovascular risk. Sports Med 2012;42:119-34.
9. Appleby M, Fisher M, Martin M. Myocardial infarction, hyperkalaemia and ventricular tachycardia in a young male body-builder. Int J Cardiol 1994;44:171-4. (Pubitemid 24156364)
10. Santamarina RD, Besocke AG, Romano LM, et al. Ischemic stroke related to anabolic abuse. Clin Neuropharmacol 2008;31:80-5. (Pubitemid 351489333)
11. Liljeqvist S, Hellden A, Bergman U, et al. Pulmonary embolism associated with the use of anabolic steroids. Eur J Intern Med 2008;19:214-15. (Pubitemid 351459624)
12. Lunghetti S, Zaca V, Maffei S, et al. Cardiogenic shock complicating myocardial infarction in a doped athlete. Acute Card Care 2009;11:250-1.
13. Fineschi V, Riezzo I, Centini F, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med 2007;121:48-53. (Pubitemid 46009473)
14. Ment J, Ludman PF. Coronary thrombus in a 23 year old anabolic steroid user. Heart 2002;88:342.
15. Mark PB, Watkins S, Dargie HJ. Cardiomyopathy induced by performance enhancing drugs in a competitive bodybuilder. Heart 2005;91:888.
16. Ahlgrim C, Guglin M. Anabolics and cardiomyopathy in a bodybuilder: case report and literature review. J Card Fail 2009;15:496-500.
17. Frogel JK, Weiss SJ, Kohl BA. Transesophageal echocardiography diagnosis of coronary sinus thrombosis. Anesth Analg 2009;108:441-2.
18. Sullivan ML, Martinez CM, Gallagher EJ. Atrial fibrillation and anabolic steroids. J Emerg Med 1999;17:851-7. (Pubitemid 29444574)
19. Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy 2005;25:756-61. (Pubitemid 40604891)
20. Alhadad A, Acosta S, Sarabi L, et al. Pulmonary embolism associated with protein C deficiency and abuse of anabolic-androgen steroids. Clin Appl Thromb Hemost 2010;16:228-31.
21. Wysoczanski M, Rachko M, Bergmann SR. Acute myocardial infarction in a young man using anabolic steroids. Angiology 2008;59:376-8. (Pubitemid 351793151)
22. Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med Sci Sports Exerc 1992;24:633-7.
23. Gunes Y, Erbas C, Okuyan E, et al. Myocardial infarction with intracoronary thrombus induced by anabolic steroids. Anadolu Kardiyol Derg 2004;4:357-8. (Pubitemid 39654422)
24. Lane HA, Grace F, Smith JC, et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest 2006;36:483-8. (Pubitemid 43876128)
25. Grace FM, Davies B. Raised concentrations of C reactive protein in anabolic steroid using bodybuilders. Br J Sports Med 2004;38:97-8. (Pubitemid 38183615)
26. Freed DL, Banks AJ, Longson D, et al. Anabolic steroids in athelics: crossover double-blind trial on weightlifters. Br Med J 1975;2:471-3.
27. Angell P, Chester N, Green DJ, et al. Anabolic steroid use and longitudinal, radial and circumferential cardiac motion. Med Sci Sports Exerc 2012;44:583-90.
28. Hartgens F, Rietjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 2004;38:253-9. (Pubitemid 38748112)
29. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004;34:513-54. (Pubitemid 38981844)
30. Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metabolism 1987;36:949.
31. Zmuda JM, Bausserman LL, Maceroni D, et al. The effect of supraphysiologic doses of testosterone on fasting total homocysteine levels in normal men. Atherosclerosis 1997;130:199-202. (Pubitemid 27191041)
32. Graham MR, Grace FM, Boobier W, et al. Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse. Br J Sports Med 2006;40:644-8. (Pubitemid 44032655)
33. Alen M. Androgenic steroid effects on liver and red cells. Br J Sports Med 1985;19:15-20.
34. Savage DD, Levy D, Dannenberg AL, et al. Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol 1990;65:371-6. (Pubitemid 20038922)
35. Sachtleben TR, Berg KE, Elias BA, et al. The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc 1993;25:1240-5. (Pubitemid 23326476)
36. Nottin S, Nguyen LD, Terbah M, et al. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am J Cardiol 2006;97:912-15.
37. D'Andrea A, Caso P, Salerno G, et al. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br J Sports Med 2007;41:149-55. (Pubitemid 46579900)
38. Baggish AL, Weiner RB, Kanayama G, et al. Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circ Heart Fail 2010;3:472-6.
39. Kasikcioglu E, Oflaz H, Umman B, et al. Androgenic anabolic steroids also impair right ventricular function. Int J Cardiol 2009;134:123-5.
40. Ebenbichler CF, Sturm W, Ganzer H, et al. Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 2001;158:483-90. (Pubitemid 32913661)
41. Anti-Doping U. UK National Anti-Doping Programme Quarterly Report. 2011.
42. George AJ. The anabolic steroids and peptide hormones. In: Mottram, D. Drugs in Sport, 2nd edn S 1996:173-18.
43. Hartgens F, Van Marken Lichtenbelt WD, Ebbing S, et al. Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration. Int J Sports Med 2001;22:235-41. (Pubitemid 32336880)
44. Melnik B, Jansen T, Grabbe S. Abuse of anabolic†androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges 2007;5:110-17. (Pubitemid 46212727)
45. Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart 2000;83:627.
46. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-8. (Pubitemid 32104128)
47. Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance. JAMA 2003;289:1537.
48. To L, Sangster J, Rampling D, et al. Ephedrine-induced cardiomyopathy. Med J Aust 1980;2:35.
49. Bruno A, Nolte KB, Chapin J. Stroke associated with ephedrine use. Neurology 1993;43:1313.
50. Cantu C, Arauz A, Murillo-Bonilla LM, et al. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke 2003;34:1667-72. (Pubitemid 36842622)
51. Wiener I, Tilkian AG, Palazzolo M. Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion. Cathete Cardiovasc Diagn 1990;20:51-3. (Pubitemid 20249771)
52. Drew C, Knight G, Hughes D, et al. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. Br J Clin Pharmacol 1978;6:221.
53. Bye C, Hill H, Hughes D, et al. A comparison of plasma levels of L (+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. Eur J Clin Pharmacol 1975;8:47-53.
54. Empey D, Young G, Letley E, et al. Dose-response study of the nasal decongestant and cardiovascular effects of pseudoephedrine. Br J Clin Pharmacol 1980;9:351.
55. Bright T, Sandage B, Fletcher H. Selected cardiac and metabolic responses to pseudoephedrine with exercise. J Clini Pharmacol 1981;21:488.
56. Haller CA, Jacob P, Benowitz NL. Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. Clini Pharmacol Ther-St Louis-. 2002;72:421-32. (Pubitemid 34701349)
57. Kaye S, McKetin R, Duflou J, et al. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction 2007;102:1204-11 [Research Support, Non-U.S. Gov't Review] (Pubitemid 47039146)
58. Fletcher K, Collinson J. Cracking down on the problem. Br J Cardiol 2011;18:102-3.
59. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med 2001;345:351-8. (Pubitemid 32703239)
60. Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation 2010;122:2558-69.
61. Maraj S, Figueredo VM, Lynn Morris D. Cocaine and the heart. Clin Cardiol 2010;33:264-9.
62. Lange RA, Cigarroa RG, Yancy CW Jr, et al. Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 1989;321:1557-62. (Pubitemid 20008233)
63. Heesch CM, Wilhelm CR, Ristich J, et al. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart 2000;83:688.
64. Hollander JE, Hoffman RS. Cocaine-induced myocardial infarction: an analysis and review of the literature. J Emerg Med 1992;10:169-77.
65. Dressler FA, Malekzadeh S, Roberts WC. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts. Am J Cardiol 1990;65:303-8. (Pubitemid 20038910)
66. Satran A, Bart BA, Henry CR, et al. Increased prevalence of coronary artery aneurysms among cocaine users. Circulation 2005;111:2424-9. (Pubitemid 40696129)
67. Hsue PY, Salinas CL, Bolger AF, et al. Acute aortic dissection related to crack cocaine. Circulation 2002;105:1592-5. (Pubitemid 34297638)
68. Martinez N, Diez-Tejedor E, Frank A. Vasospasm/thrombus in cerebral ischemia related to cocaine abuse. Stroke 1996;27:147.
69. Nanji AA, Filipenko JD. Asystole and ventricular fibrillation associated with cocaine intoxication. Chest 1984;85:132-3. (Pubitemid 14215321)
70. Isner JM, Chokshi SK. Cardiovascular complications of cocaine. Curr Probl Cardiol 1991;16:89.
71. Hogya PT, Wolfson AB. Chronic cocaine abuse associated with dilated cardiomyopathy. Am J Emerg Med 1990;8:203.
72. Mehta A, Jain AC, Mehta MC, et al. Caffeine and cardiac arrhythmias. An experimental study in dogs with review of literature. Acta Cardiol 1997;52:273.
73. Berger AJ, Alford K. Cardiac arrest in a young man following excess consumption of caffeinated 'energy drinks'. Med J Aust 2009;190:41-3.
74. Forman J, Aizer A, Young CR. Myocardial infarction resulting from caffeine overdose in an anorectic woman. Ann Emerg Med 1997;29:178-80. (Pubitemid 27030040)
75. Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl J Med 1986;314:271-5. (Pubitemid 16146599)
76. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coronary spasm. Circulation 1993;87:76-9. (Pubitemid 23019336)
77. Newby DE, Wright RA, Labinjoh C, et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 1999;99:1411-15. (Pubitemid 29140904)
78. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke. JAMA 1988;259:1025-9. (Pubitemid 18046850)
79. Ottervanger JP, Festen JM, de Vries AG, et al. Acute myocardial infarction while using the nicotine patch. Chest 1995;107:1765-6.
80. Arnaot MR. Treating heart disease. Nicotine patches may not be safe. BMJ 1995;310:663.
81. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8. (Pubitemid 26412397)